Execution of a Loan Agreement with Financial Covenants
GNI Group Ltd. (filing company)
Common shares of Gyre Therapeutics, Inc. (collateral) / acquisition of shares in あゆみ製薬ホールディングス (use of funds)
Borrowing to fund the acquisition of shares in あゆみ製薬ホールディングス and related expenses
not disclosed (the impact on consolidated results for the current fiscal year is currently under review)
The impact on the company's consolidated results for the current fiscal year is currently under review. The company will promptly disclose any matters requiring disclosure that arise in the future.
The borrowing date is 1 July 2026, and the repayment due date is 1 July 2027. The company will review the impact on consolidated results for the current fiscal year and promptly disclose any matters requiring disclosure that arise.
The company will promptly disclose any matters requiring disclosure that arise in the future.
| Item | Details |
|---|---|
| Event name | Execution of a Loan Agreement with Financial Covenants |
| Date of occurrence | 26 June 2026 (agreement execution date) |
| Subject Entity | GNI Group Ltd. (filing company) |
| Target Locations / Products | Common shares of Gyre Therapeutics, Inc. (collateral) / acquisition of shares in あゆみ製薬ホールディングス (use of funds) |
| Cause | Borrowing to fund the acquisition of shares in あゆみ製薬ホールディングス and related expenses |
| Amount of Impact on Business Performance | not disclosed (the impact on consolidated results for the current fiscal year is currently under review) |
| Impact on Earnings Forecast | The impact on the company's consolidated results for the current fiscal year is currently under review. The company will promptly disclose any matters requiring disclosure that arise in the future. |
| Outlook | The borrowing date is 1 July 2026, and the repayment due date is 1 July 2027. The company will review the impact on consolidated results for the current fiscal year and promptly disclose any matters requiring disclosure that arise. |
| Planned follow-up disclosure | The company will promptly disclose any matters requiring disclosure that arise in the future. |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To fund the acquisition of shares in あゆみ製薬ホールディングス and related expenses.